INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus
2 other identifiers
observational
243
1 country
16
Brief Summary
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 3, 2011
CompletedFirst Posted
Study publicly available on registry
June 7, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2015
CompletedResults Posted
Study results publicly available
April 27, 2016
CompletedApril 27, 2016
March 1, 2016
4.2 years
June 3, 2011
March 25, 2016
March 25, 2016
Conditions
Outcome Measures
Primary Outcomes (5)
Progression-free Survival (PFS)
Progression-free survival: interval between start of treatment to first day when progressive disease (PD) was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) for participants with RCC and Cheson criteria for participants with MCL, or death due to any cause. RECIST criteria: at least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum. In addition to relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). Appearance of one or more new lesions also considered progression. Cheson criteria: appearance of any new sites of lymphoma OR at least 50% increase in product of longest perpendicular dimensions of any previously identified lymph node mass (LNM) OR at least 50% increase in longest dimension of any previously identified LNM greater than 1 cm in longest transverse dimension OR at least 50% increase in size of any previously involved site of lymphoma.
From initiation of treatment up to disease progression (up to 80 months)
Percentage of Participants With Objective Response
Objective response: percentage of participants who achieved complete remission (CR) or partial response (PR). RECIST criteria was used for participants with RCC and Cheson criteria for participants with MCL. RECIST criteria (CR: disappearance of all target lesions, any pathological lymph nodes(target or non-target) reduced in short axis to \<10 mm, PR: at least 30% decrease in sum of diameters of target lesions). Cheson criteria (CR: all lymph node masses regressed to normal size, each lymph node mass that was \>1.5 cm in longest transverse dimension regressed to \<=1.5 cm, lymph node mass that was 1.1-1.5 cm regressed to \<=1 cm, complete disappearance of all radiographic evidence of disease, PR: at least 50% decrease in sum of products of the longest perpendicular dimensions of the previously identified dominant lymph node masses, no increase in size of other lymph nodes.)
From initiation of treatment up to disease progression (up to 80 months)
Duration of Response (DOR)
Duration of response (DOR) was defined as the interval from the date the response was documented to the first date that progression of disease (PD) was observed in participants with PR or CR. RECIST criteria was used for participants with RCC and Cheson criteria for participants with MCL. PD, CR and PR are defined in primary outcome 1 and 2.
From initiation of treatment up to disease progression (up to 80 months)
Overall Survival (OS)
Overall survival (OS) was defined as the interval from the day of the start of the treatment to death, or censored to the last date when the participant was identified to be alive.
From initiation of treatment untill death (up to 80 months)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-serious adverse events (Non-SAEs).
Baseline to the 28 calendar days after the last administration of study drug (upto 80 months)
Study Arms (1)
Patients that received treatment with Temsirolimus
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Interventions
There is not any intervention in this study.
Eligibility Criteria
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
You may qualify if:
- Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
You may not qualify if:
- Patients that do not have a minimum (pre-specified) of data in their clinical record.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (16)
Complexo Hospitalario Universitario A Coruña
A Coruña, A Coruña, 15006, Spain
Hospital de La Santa Creu I Sant Pau
Barcelona, Barcelona, 08025, Spain
Hospital Vall D'Hebron
Barcelona, Barcelona, 08035, Spain
Hospital del Mar
Barcelona, Barcelona, 8940, Spain
Hospital de Cabueñes
Cabueñes, Gijon, 33394, Spain
Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera
A Coruña, La Coruña, 15006, Spain
Hospital Clinico Universitario
Santiago de Compostela, La Coruña, 15706, Spain
Complejo Hospitalario Materno-Infantil Insular de Las Palmas
Las Palmas de Gran Canaria, Las Palmas, 35016, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Madrid, 28007, Spain
Hospital Universitario La Paz
Madrid, Madrid, 28046, Spain
Hospital de Madrid Norte - Sanchinarro
Madrid, Madrid, 28050, Spain
Hospital de Navarra
Pamplona, Navarre, 31008, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33006, Spain
Hospital Provincial de Castellon
Castellon, Valencia, 12002, Spain
Complejo AAsistencial de Avilla
Ávila, 05004, Spain
MD Anderson Cancer Center
Madrid, 28033, Spain
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Pfizer ClinicalTrials.gov Call Center
- Organization
- Pfizer, Inc.
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 3, 2011
First Posted
June 7, 2011
Study Start
January 1, 2011
Primary Completion
April 1, 2015
Study Completion
April 1, 2015
Last Updated
April 27, 2016
Results First Posted
April 27, 2016
Record last verified: 2016-03